7 August 2026

1QFY27 Result Update | Sector: Utilities

Premier Energies

Estimate change	⟷
TP change	⟷
Rating change	⟷

Bloomberg	PREMIERE IN
Equity Shares (m)	454
M.Cap.(INRb)/(USDb)	475.4 / 5
52-Week Range (INR)	1134 / 660
1, 6, 12 Rel. Per (%)	2/36/-
12M Avg Val (INR M)	1639

Financial Snapshot (INR b)

Y/E March	FY26	FY27E	FY28E
Sales	78.2	131.3	186.5
Sales Gr. %	20.0	67.8	42.1
EBITDA	23.8	35.0	45.2
EBITDA margin %	30.4	26.6	24.3
Adj. PAT	15.1	18.9	22.5
EPS (INR)	33.3	41.8	49.7
EPS Gr. (%)	61.1	25.5	18.9
BV/Sh. (INR)	95.1	135.9	184.6
Ratios			
ND/Equity	0.4	0.7	0.7
ND/EBITDA	0.6	1.2	1.2
RoE (%)	42.4	36.2	31.0
RoIC (%)	63.4	42.7	32.4
Valuations			
P/E (x)	27.5	22.0	18.5
EV/EBITDA (x)	18.1	13.1	10.4

Shareholding Pattern (%)

As On	Jun-26	Mar-26	Jun-25
Promoter	58.5	63.9	64.3
DII	18.0	13.7	13.0
FII	8.5	6.1	5.1
Others	15.1	16.3	17.7

CMP: INR1,047 TP: INR1,240 (+18%) Buy

Sustained margins and capacity expansion support outlook

- Premier Energies (PEL) reported a strong 1QFY27. Its revenue was 6% higher than estimated at INR24.6b. EBITDA stood at INR7.1b, beating our est. by 13% as the EBITDA margin was 29% (vs. est. of 27%). APAT beat our est. by 25% at INR4.6b, driven by lower-than-expected interest costs. Module/cell production was 953/844MW with a CUF of 63%/92% in 1Q.
- **Key things we liked about the result:** 1) EBITDA margins were sustained during the quarter at 29%, and the company maintains industry-leading cell utilization levels, with Cell CUF at 92%; 2) 7GW cell plant commissioning remains on track with trial production expected in Aug'26; CUF targeted at ~50–60% from Nov'26 and 70% by 4QFY27; 3) EBITDA margin guidance of 29-30% was maintained; and 4) PEL is in advanced stages of setting up a European office and building a dedicated sales team.
- **Key monitorables:** 1) Timely commissioning and ramp-up of upcoming 7GW cell manufacturing capacity, 2) Progress on the US cell manufacturing JV, with location finalization underway and production expected to commence in 24–30 months; and 3) flow of new DCR orders amid partial extension of ALMM-II.
- **Valuation & view:** We value the domestic module business at 14x FY28E EBITDA and the new business segment at 10x FY28E EBITDA. The sum of these segment valuations (adjusting for net debt) leads to our TP of INR1,240.

Beat on earnings; margins sustain

Financial performance

- Quarterly revenue came in 6% higher than our est. at INR24.6b (+35% YoY, +10% QoQ).
- EBITDA stood at INR7.1b (+30% YoY, +6% QoQ), beating our est. by 13%; the EBITDA margin stood at 29% (vs. our est. of 27%).
- APAT stood at INR4.6b (+50% YoY, +1% QoQ), 25% ahead of our estimate, driven by lower-than-expected interest costs.
- PEL achieved module/cell production of 953MW/844MW with a CUF of 63%/92%.

Other highlights

- The order book stood at INR150b (40% module, 58% cell, and 2% transformers) vs. INR140b at the end of 4QFY26.
- Revenue from the sale of Power Transmission & Distribution (T&D) equipment segment contributed INR1.06b (4.5% of total revenue) post its acquisition of Transcon.
- Transcon reported an EBITDA of INR294m. Its present capacity of 6.75GVA is expected to rise to 16.75GVA by Sep'26.
- The revenue/WP of modules produced stood at INR18.3 (INR20.9/ INR18.3 in 4QFY26/1QFY26).
- The 7GW cell plant is likely to start a trial run by the end of Aug'26.

Abhishek Nigam – Research Analyst (Abhishek.Nigam@MotilalOswal.com)

Preksha Daga – Research Analyst (Preksha.Daga@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights of the 1QFY27 performance

- The 5.1GW Seetharampur module plant is fully operational, while revenue contribution from the 7GW cell plant is expected to commence from Sep'26.
- The 1QFY27 capex stood at INR15b, while management ruled out near-term equity raising, with the recent cell and module expansion largely funded through equity.
- The company secured INR30.1b of new cell and module orders in 1QFY27, taking the order book to INR150b, with 40–45% executable in FY28.
- Management expects India's solar installations to reach 20–24GW (DC) over the next nine months, driven by PM Kusum and PM Suryaghar.
- Management reiterated its 29–30% EBITDA margin guidance, aided by strong FY27–28 demand, a favorable DCR mix, and ramp-up of the 7GW cell line.
- Management is accelerating its international expansion, with a US cell manufacturing JV progressing and a European sales platform under development.

Valuation and view

- The valuation of PEL has been derived through a sum-of-the-parts (SoTP) methodology: The domestic module business is valued at 14x FY28E EBITDA. The new business segment is valued at 10x FY28E EBITDA, consistent with domestic peer valuations. The sum of these segment valuations (adjusting for net debt) leads to our TP of INR1,240.

Consolidated performance INRm

Y/E March	FY26				FY27E				FY26	FY27E	FY27	Var.	YoY	QoQ
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE			1QE	(%)	(%)	(%)
Net Sales	**18,207**	**18,369**	**19,365**	**22,303**	**24,626**	**27,059**	**36,128**	**43,481**	**78,244**	**1,31,294**	**23,322**	**6**	**35**	**10**
YoY Change (%)	9.9	20.3	13.0	37.6	35.3	47.3	86.6	95.0	20.0	67.8	20.4			
Total Expenditure	12,725	12,760	13,432	15,555	17,482	19,744	26,752	32,358	54,471	96,337	16,991	**3**	**37**	**12**
EBITDA	**5,483**	**5,609**	**5,932**	**6,748**	**7,144**	**7,315**	**9,376**	**11,122**	**23,772**	**34,957**	**6,332**	**13**	**30**	**6**
YoY Change (%)	53.0	47.4	15.5	27.7	30.3	30.4	58.0	64.8	33.5	47.0				
Margin (%)	30.1	30.5	30.6	30.3	29.0	27.0	26.0	25.6	30.4	26.6	27.1			
Depreciation	1,575	1,457	702	791	956	1,403	2,456	3,955	4,525	8,770	911	5	-39	21
Interest	368	325	474	415	439	874	1,113	1,547	1,582	3,973	682	-36	19	6
Other Income	488	845	297	386	450	495	661	1,020	2,015	2,626	352	28	-8	17
PBT before EO expense	**4,027**	**4,672**	**5,053**	**5,928**	**6,198**	**5,533**	**6,469**	**6,640**	**19,681**	**24,839**	**5,091**			
Extra-Ord income/(exp.)	0	0	0	0	0	0	0	0	0	0	0			
PBT	**4,027**	**4,672**	**5,053**	**5,928**	**6,198**	**5,533**	**6,469**	**6,640**	**19,681**	**24,839**	**5,091**	**22**	**54**	**5**
Tax	952	1,138	1,136	1,410	1,485	1,273	1,488	1,469	4,635	5,714	1,392			
Rate (%)	23.6	24.3	22.5	23.8	24.0	23.0	23.0	22.1	23.6	23.0	27.3			
Minority Interest	0	0	-1	0	89	47	47	6	-1	189	-1			
Share of JV & associates	2	0	-1	50	5	1	1	-3	51	5	-1			
Reported PAT	**3,078**	**3,534**	**3,917**	**4,568**	**4,631**	**4,214**	**4,935**	**5,162**	**15,098**	**18,941**	**3,699**	**25**	**50**	**1**
Adj PAT	**3,078**	**3,534**	**3,917**	**4,568**	**4,631**	**4,214**	**4,935**	**5,162**	**15,098**	**18,941**	**3,699**	**25**	**50**	**1**
YoY Change (%)	39.5	47.9	38.6	45.7	34.0	14.7	24.1	12.0	161.1	125.5	(5.6)			
Margin (%)	16.9	19.2	20.2	20.5	18.8	15.6	13.7	11.9	19.3	14.4	15.9			

Exhibit 1: Valuation Summary

Sum of the parts valuation		Unit	FY28	Multiple	EV
Domestic Modules	INR mn	EBITDA	40,892	14	5,72,490
New businesses	INR mn	EBITDA	4,350	10	45,592
Total EV	**INR mn**				**6,18,081**
Net debt	INR mn				56,233
Market Cap	**INR mn**				**5,61,848**
NOSH	Mn				453
Target price	**INR**				**1,240**
CMP	INR				1,047
Upside / (Downside)	**%**				**18%**

Source: Company, MOFSL



Highlights from the management commentary

Cell and Module Capacity

- 5.1GW Seetharampur module plant is fully operational.
- 7GW cell plant revenue contribution should start from September, with trial production starting this month, 50-60% CUF from Nov'26 and 70% CUF targeted in 4QFY27.
- Have a healthy pipeline over the next 18 months for cell orders.

Corporate Structure, Capital and Capex

- Capex in 1QFY27 was INR15b, of which INR2.5b was for Transcon and the rest on solar projects.
- The bulk of financing for the new cell and module capacity has been equity, and there has not been much increase in finance cost after commissioning of the same.
- No plan to raise primary capital in the near future.
- Post TOPCon, the company is looking at TOPCon Black Contact (TBC) and then possibly tandem cells.

Order Book and Sales Mix

- Won new orders of INR30.1b for cells and modules in 1QFY27, most of which were DCR orders.
- Of the INR150b order book, at least 40-45% will go into FY28.
- Module orders in the orderbook are for FY27 and cell orders are for FY28-29, so the cell order share looks higher in the orderbook.
- Non-DCR module order inflow increased due to the ALMM-II partial extension, which was positive for PEL as module capacity is more than cell capacity.
- Non-DCR modules are not profitable, though there was a slight increase in margins in non-DCR modules during this quarter.
- As PEL moves forward, the DCR module share will go up in revenue versus only cells.
- Cell order pricing is variable based on silver, forex and other inputs, though prices are stable.

Industry Demand, PM Kusum and DC Overloading

- India added 12GW of solar in 1QFY27, and should do 20-24GW (DC) in the next nine months from PM Suryaghar and PM Kusum.

- DC overloading for PM Kusum runs across three components, A, B and C, with most installations happening in B and C. Solar pumps (B) have 1x overloading and ground-mounted (C) has 1.3x and 1.5x, so blended overloading is 1.2-1.25x.
- Mar'27 is the cut-off date for implementation of ongoing PM Kusum projects, so installations should be 6-8GW (AC) or higher in the next 9months. 10-12GW of PMSGY AC additions expected.
- PM Kusum and PM Suryaghar are getting over in Mar'26, so 2.0 versions may come in, and DCR demand may be significant from 4QFY27 onwards.
- New demand should come in the C&I segment from 1 Jan'27 onwards under ALMM-II, so demand should start coming in during 3QFY27 onwards.
- Realizations are ~24-25cents/Wp for PM Suryaghar and ~22 cents/Wp for PM Kusum, with C&I a little lower given larger scale.

Margins and Demand Outlook

- FY27 and FY28 demand is strong, and supply is constrained as new capacity and ramp-up are taking time. C&I clients are very selective and have started placing orders for FY28, blocking capacities from players with proven track records.
- The orderbook has similar margins to what is being delivered now at 29-30%, and the new cell line will give operational leverage as the DCR order mix increases.
- 29-30% EBITDA margin guidance will be maintained, backed by the new 7GW cell line, transformer capacity going up, and the ingot-wafer line also coming up in FY28.
- Not much movement in DCR spreads. Silver has dropped, but contracts are priced in dollars, so they are not much affected by the forex change. The company takes hedging positions for aluminum and silver.

Costs and Depreciation

- The jump in other expenses is due to hiring and training expenses for the new Naidupeta plant.
- Seetharampur module line has 40% lower employee cost/GW.
- Depreciation follows a 5-year schedule for all cell and module lines. The next two quarters will see depreciation increase as the Seetharampur module line has started, and once new cell capacity starts, the run-rate would be INR2.4-2.5b quarterly from 4Q onwards.

Transformers (Transcon) and BESS

- Margin guidance - higher than 15% EBITDA and 8-10% PAT.
- Exports are being looked at in North America, Europe and Africa. Revenue was INR4b for FY26, with INR12b+ expected by FY29.
- On BESS, land has been acquired, and construction has started for Phase 1. Partners for a containerized solution are being evaluated and should be finalized in 2-3 months, while regulatory clarity is awaited.
- Storage has become viable given cost and arbitrage of INR6-7, and 20GWh of storage capacity is expected this year.

International Expansion and Technology

- US
  - A JV is in place to set up cell manufacturing in the US, with the location being finalized now and concrete plans in place. With the Minimum Import Price proposal, it makes sense to manufacture in the US, and production can be expected to start in 24-30 months.
- Europe
  - PEL is in advanced stages of opening a European office and building a sales team there.
  - Tenders have started to come out, and the market should open up substantially due to non-Chinese requirements, particularly Italy, France and Germany.
  - Policy is still taking shape, and module imports from an FTA partner into the EU should receive the same treatment as domestic EU supply.
  - Exports from India are the first preference, and at some point PEL may look at setting up a plant depending on demand growth and policies.


Story in charts – 1QFY27

Exhibit 2: Operational Snapshot

Particulars	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	4QFY26	1QFY27
Capacity							
Module (GW)	4.1	4.1	5.1	5.1	5.1	11.1	11.1
Cell (GW)	2.0	2.0	3.2	3.2	3.2	3.6	3.6
Transformers (GVA)							6.8
Production							
Module (GW)	0.7	0.7	0.7	1.0	1.0	0.9	1.0
Cell (GW)	0.5	0.5	0.4	0.5	0.6	0.7	0.8
Transformers (GVA)							0.6
CUF							
Module	74.0%	75.0%	77.0%	79.0%	78.0%	73.0%	63.0%
Cell	96.0%	95.0%	94.0%	79.0%	83.0%	84.0%	92.0%
Revenue Breakup (INRb)	**16.4**	**15.2**	**17.7**	**17.6**	**18.8**	**21.9**	**24.6**
Module	10.5	11.3	13.5	13.2	14.5	19.2	17.5
Cell	6.0	3.9	4.2	4.4	4.3	2.7	5.9
Transcon							1.0
Exports							0.2
Order Book (INRb)	**69.5**	**85.3**	**86.0**	**131.3**	**137.4**	**140.1**	**150.0**
Module	43.8	61.7	51.6	53.0	63.1	58.8	60.0
Cell	25.0	22.8	33.6	78.2	74.1	81.3	87.0
Transformers	-	-	-	-	-	-	3.0
EPC	0.7	0.8	0.9	0.1	0.1	-	-


Source: Company, MOFSL

Exhibit 3: Revenue and APAT trends (INRb)




Source: Company, MOFSL

Exhibit 4: EBITDA and EBITDA margin trends (%)




Source: Company, MOFSL

Exhibit 5: Quarterly revenue and APAT trends (INRb)




Source: Company, MOFSL

Exhibit 6: Quarterly EBITDA (INRb) and EBITDA margin (%)




Source: Company, MOFSL

Exhibit 7: Manufacturing capacity (GW)



Source: Company, MOFSL

Exhibit 8: Quarterly module and cell production (GW)



Source: Company, MOFSL

Financials and valuations

Consolidated Income Statement					INR m
Y/E March	**FY24**	**FY25**	**FY26**	**FY27E**	**FY28E**
Net Sales	**31,438**	**65,187**	**78,244**	**1,31,294**	**1,86,504**
Change (%)	*120%*	*107%*	*20%*	*68%*	*42%*
Total Expenses	26,660	47,379	54,471	96,337	1,41,262
EBITDA	**4,778**	**17,809**	**23,772**	**34,957**	**45,242**
EBITDAM (%)	*15%*	*27%*	*30%*	*27%*	*24%*
Depn. & Amortization	961	4,975	4,525	8,770	14,678
EBIT	**3,817**	**12,834**	**19,247**	**26,187**	**30,565**
Net Interest and finance cost	1,212	1,774	1,582	3,973	5,953
Other income	275	1,333	2,015	2,626	4,663
PBT before extraordinary items	**2,880**	**12,393**	**19,681**	**24,839**	**29,274**
EO income/ (expense)	-	-	-	-	-
PBT	**2,880**	**12,393**	**19,681**	**24,839**	**29,274**
Tax	580	3,028	4,635	5,714	6,440
Rate (%)	*20%*	*24%*	*24%*	*23%*	*22%*
JV/Associates	13	7	51	5	-
Reported PAT	**2,314**	**9,371**	**15,097**	**19,130**	**22,834**
Minority	-	-	(1)	189	320
Adjusted PAT	**2,314**	**9,371**	**15,098**	**18,941**	**22,513**
YoY change (%)	*-1907%*	*305%*	*61%*	*25%*	*19%*

Consolidated Balance Sheet					INR m
As on Y/E March	**FY24**	**FY25**	**FY26**	**FY27E**	**FY28E**
Share Capital	263	451	453	453	453
Reserves	6,205	27,770	42,624	61,112	83,173
Net Worth	**6,469**	**28,221**	**43,077**	**61,565**	**83,626**
Minority Interest	130	0	26	216	536
Total Loans	13,922	18,935	36,168	63,168	85,668
Capital Employed	**20,521**	**47,156**	**79,272**	**1,24,949**	**1,69,830**
Net Fixed Assets	**11,974**	**9,726**	**17,411**	**41,861**	**54,560**
Capital WIP	198	2,420	21,439	33,219	50,843
Goodwill	0	0	0	0	0
Investments	148	8,511	6,752	6,752	6,752
Curr. Assets	**23,221**	**47,756**	**62,847**	**81,558**	**1,06,189**
Inventories	10,093	13,256	20,374	32,689	41,577
Account Receivables	6,090	8,009	9,828	16,491	23,426
Cash and Cash Equivalents	4,027	20,023	20,895	20,628	29,435
Others	3,011	6,468	11,750	11,750	11,750
Curr. Liability & Prov.	**15,020**	**21,258**	**29,177**	**38,441**	**48,513**
Account Payables	9,746	9,647	11,550	20,814	30,886
Provisions & Others	5,274	11,611	17,627	17,627	17,627
Net Curr. Assets	**8,201**	**26,498**	**33,670**	**43,117**	**57,676**
Appl. of Funds	**20,521**	**47,156**	**79,271**	**1,24,949**	**1,69,830**

Financials and valuations

Consolidated Cash Flow Statement					INR m
Particulars	**FY24**	**FY25**	**FY26**	**FY27E**	**FY28E**
Profit/(loss) for the year before tax	**2,893**	**12,400**	**19,681**	**24,839**	**29,274**
Depreciation	961	4,975	4,525	8,770	14,678
Others	(2,701)	99	(7,565)	(8,367)	(4,460)
Direct taxes (net)	(252)	(3,994)	(4,082)	(5,714)	(6,440)
CF from Op. Activity	**901**	**13,480**	**12,559**	**19,528**	**33,051**
Capex	(4,514)	(6,202)	(29,977)	(45,000)	(45,000)
FCFF	**(3,612)**	**7,278**	**(17,418)**	**(25,472)**	**(11,949)**
Interest income	65	671	837	2,626	4,663
Others	(18)	(18,572)	7,582	-	-
CF from Inv. Activity	**(4,466)**	**(24,103)**	**(21,559)**	**(42,374)**	**(40,337)**
Share capital	-	12,468	-	-	-
Borrowings	6,287	5,012	7,233	27,000	22,500
Finance cost	(785)	(1,105)	(1,166)	(3,973)	(5,953)
Dividend	-	(224)	(336)	(453)	(453)
Others	(13)	(73)	9,857	-	-
CF from Fin. Activity	**5,489**	**16,078**	**15,588**	**22,574**	**16,094**
(Inc)/Dec in Cash	**1,924**	**5,456**	**6,588**	**(273)**	**8,807**
Opening balance	646	2,570	8,026	14,665	14,398
Closing balance (as per B/S)	**2,570**	**8,026**	**14,665**	**14,398**	**23,205**

Ratios					
Particulars	**FY24**	**FY25**	**FY26**	**FY27E**	**FY28E**
Basic (INR)					
EPS	5.1	20.7	33.3	38.6	50.2
Cash EPS	7.2	31.7	43.3	58.8	82.6
BV/Share	14.3	62.3	95.1	132.7	181.9
DPS		0.5	1.0	1.0	1.0
Payout (%)		2.4	3.0	2.6	2.0
Dividend yield (%)		0.1	0.1	0.1	0.1
Valuation (x)					
P/E	NA	44.4	27.5	23.8	18.3
Cash P/E	NA	29.0	21.2	15.6	11.1
P/BV	NA	14.7	9.7	6.9	5.0
EV/EBITDA	3.4	23.3	18.1	13.7	10.8
Return Ratios					
RoE	44%	54%	42%	34%	32%
RoCE (post-tax)	20%	32%	26%	20%	19%
RoIC (post-tax)	28%	60%	63%	40%	31%
Working Capital Ratios					
Fixed Asset Turnover (x)	2.6	6.7	4.5	3.2	3.5
Asset Turnover (x)	1.5	1.4	1.0	1.1	1.1
Debtor (Days)	71	45	46	46	46
Inventory (Days)	154	118	157	140	120
Payable (Days)	149	86	89	89	89
Working Capital (Days)	76	77	114	97	77
Leverage Ratio (x)					
Net Debt/Equity	1.5	(0.0)	0.4	0.7	0.7
Net Debt/EBITDA	2.1	(0.1)	0.6	1.2	1.2

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

Explanation of Investment Rating	
Investment Rating	**Expected return (over 12-month)**
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore.This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

.

Specific Disclosures

1. Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
   MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
   MOFSL may have received compensation from the subject company(ies) in the past 12 months.
4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
5. Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

****

The associates of MOFSL may have:
financial interest in the subject company
actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
received compensation/other benefits from the subject company in the past 12 months
any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
Served subject company as its clients during twelve months preceding the date of distribution of the research report.
The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN .: 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.